Literature DB >> 3102546

Sex steroids and pulsatile luteinizing hormone release in men. Studies in estrogen-treated agonadal subjects and eugonadal subjects treated with a novel nonsteroidal antiandrogen.

L Gooren, T Spinder, J J Spijkstra, H van Kessel, A Smals, B R Rao, M Hoogslag.   

Abstract

This study evaluated the effects of estrogens and androgens on LH pulse frequency and amplitude in male subjects. To assess the role of estrogens we compared the serum LH pulse frequency and amplitude between 3 groups: 8 agonadal subjects receiving no steroid treatment; 6 agonadal subjects continuously treated with 50 micrograms ethinylestradiol/day; and 17 eugonadal men. Mean serum LH levels and LH pulse amplitude were significantly lower in the agonadal subjects receiving estrogens (14.8 +/- 5.4 (SD) U/L and 4.1 +/- 1.5 U/L, respectively) than in the group of agonadal subjects not receiving sex steroid treatment (35.7 +/- 8.4 U/L and 7.3 +/- 2.0 U/L, respectively). The mean LH pulse frequency was 7.1 +/- 1.5/7 h in the group not receiving sex steroid treatment and 6.0 +/- 1.4/7 h in the group receiving estrogens (P NS). The LH pulse frequency in the eugonadal men (3.8 +/- 1.3/7 h) was significantly lower than the frequency in both groups of agonadal subjects. The LH pulse amplitude was of the same magnitude in the estrogen-treated agonadal subjects and in eugonadal men (4.1 +/- 1.5 U/L and 3.5 +/- 1.2 U/L, respectively). The role of androgens was studied in 15 eugonadal male subjects (who presented for female role reassignment) by determining the effects of a novel nonsteroidal androgen receptor blocker, Anandron, on basal and LH-releasing hormone (LHRH)-stimulated serum LH/FSH levels; LH pulse frequency and amplitude; sex steroid and sex hormone-binding globulin levels; and serum PRL levels during an 8-week period. Basal and LHRH-stimulated LH levels and testosterone rose progressively during the first 6 weeks and reached a plateau thereafter, while estradiol levels continued to increase somewhat. The LH pulse amplitude and frequency had increased after 6 weeks (3.1 +/- 0.6 vs. 4.5 +/- 1.2 U/L and 4.4 +/- 2.4 vs. 6.6 +/- 1.1 pulses/7 h, respectively). Basal FSH levels were not affected while LHRH-stimulated FSH levels progressively decreased from 2 to 6 weeks, after which they did not change. Along with the rise of estradiol levels an increase of sex hormone-binding globulin and PRL levels occurred.(ABSTRACT TRUNCATED AT 400 WORDS)

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3102546     DOI: 10.1210/jcem-64-4-763

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  10 in total

1.  Hormone pattern in pharmacologically feminized male transsexuals in the California State prison system.

Authors:  L J Valenta; A N Elias; E S Domurat
Journal:  J Natl Med Assoc       Date:  1992-03       Impact factor: 1.798

2.  Estrogen promotes Leydig cell engulfment by macrophages in male infertility.

Authors:  Wanpeng Yu; Han Zheng; Wei Lin; Astushi Tajima; Yong Zhang; Xiaoyan Zhang; Hongwen Zhang; Jihua Wu; Daishu Han; Nafis A Rahman; Kenneth S Korach; George Fu Gao; Ituro Inoue; Xiangdong Li
Journal:  J Clin Invest       Date:  2014-04-24       Impact factor: 14.808

3.  The effect of non-steroidal antiandrogen flutamide on luteinizing hormone pulsatile secretion in male-to-female transsexual subjects.

Authors:  M Giusti; M R Falivene; A Carraro; C M Cuttica; S Valenti; G Giordano
Journal:  J Endocrinol Invest       Date:  1995-06       Impact factor: 4.256

4.  Inhibition of luteinizing hormone secretion by testosterone in men requires aromatization for its pituitary but not its hypothalamic effects: evidence from the tandem study of normal and gonadotropin-releasing hormone-deficient men.

Authors:  Nelly Pitteloud; Andrew A Dwyer; Suzzunne DeCruz; Hang Lee; Paul A Boepple; William F Crowley; Frances J Hayes
Journal:  J Clin Endocrinol Metab       Date:  2007-12-11       Impact factor: 5.958

Review 5.  Nilutamide. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in prostate cancer.

Authors:  M G Harris; S G Coleman; D Faulds; P Chrisp
Journal:  Drugs Aging       Date:  1993 Jan-Feb       Impact factor: 3.923

6.  The relative role of gonadal sex steroids and gonadotropin-releasing hormone pulse frequency in the regulation of follicle-stimulating hormone secretion in men.

Authors:  Nelly Pitteloud; Andrew A Dwyer; Suzzunne DeCruz; Hang Lee; Paul A Boepple; William F Crowley; Frances J Hayes
Journal:  J Clin Endocrinol Metab       Date:  2008-04-29       Impact factor: 5.958

7.  Low serum levels of dehydroepiandrosterone may cause deficient IL-2 production by lymphocytes in patients with systemic lupus erythematosus (SLE).

Authors:  T Suzuki; N Suzuki; E G Engleman; Y Mizushima; T Sakane
Journal:  Clin Exp Immunol       Date:  1995-02       Impact factor: 4.330

8.  Effects of the pure antiandrogen RU 23.903 (anandron) on sexuality, aggression, and mood in male-to-female transsexuals.

Authors:  J F van Kemenade; P T Cohen-Kettenis; L Cohen; L J Gooren
Journal:  Arch Sex Behav       Date:  1989-06

9.  The effect of flutamide on basal and ACTH-stimulated plasma levels of adrenal androgens in patients with advanced prostate cancer.

Authors:  S Balzano; M Cappa; R Migliari; R M Scarpa; E Danielli; G Campus; C Pintus; V Sica; E Usai; E Martino
Journal:  J Endocrinol Invest       Date:  1988-11       Impact factor: 4.256

10.  Stimulation of erythropoiesis by the non-steroidal anti-androgen nilutamide in men with prostate cancer: evidence for an agonistic effect?

Authors:  A Decensi; R Torrisi; V Fontana
Journal:  Br J Cancer       Date:  1994-03       Impact factor: 7.640

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.